Smruthi Organics Ltd (BSE: 540686) is a Solapur, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹153 Cr, it ranks #2,874 by market cap among the 6,189 Indian listed companies on FinBizNet, and #59 of 86 in Medicinal Chemicals and Botanical Products. At ₹133.50 (as of 26 Oct 2026), the share price is 23.8% below its 52-week high of ₹175.30 and 40.5% above its 52-week low of ₹95.00. The share price is up 2.7% over one year and up 17.1% over three months.
| Current Price | ₹133.50 |
|---|---|
| Market Cap | ₹153 Cr |
| BSE Code | 540686 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 44.6 |
| Return on Equity | 4.72% |
| Return on Assets | 4.08% |
| 52-Week Range | ₹95.00 – ₹175.30 |
| 1-Year Price Change | +2.7% |
| 3-Month Price Change | +17.1% |
| Beta (1Y) | 0.58 |
| Dividend Yield | 1.12% |
| Headquarters | Solapur, Maharashtra |
| Website | smruthiorganics.com |
| Revenue | ₹29 Cr |
|---|---|
| Net Profit | ₹3 Cr |
| Net Margin | 10.0% |
| EPS (Basic) | ₹2.57 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Smruthi Organics Limited manufactures and markets active pharmaceutical ingredient (API) products to India. The company provides API for cardiovascular that includes amlodipine besilate, losartan potassium, telmisartan, s - amlodipine besilate, s - amlodipine malelate, and valsartan; for anti diabetic, which comprises metformin HCL, vildagliptin, teneligliptin, and dapagliflozin; and for anti infectives that consists of ciprofloxacin HCL, diloxanide furoate, norfloxacin, and pefloxacin mesylate, as well as ticagrelor for anti platelets. It also offers drug intermediates, such as amlodipine base, s-amlodipine base, and phthaloyl amlodipine. In addition, the company is developing empagliflozin for anti-diabetics; and apixaban and rivaroxaban for anti-platelets. It also exports its products. The company was incorporated in 1989 and is headquartered in Solapur, India.
1. Bulk Drugs and Drug Intermediates-This segment manufactures active pharmaceutical ingredients, such as bulk drugs and drug intermediates. 2. Formulation Division-This segment offers finished dosage formulations.
1. API-99.8% 3. Formulation-0.2%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,19,404 Cr | 36.6 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,658 Cr | 22.5 | 18.32% | ₹8,017 Cr | +14.7% |
| Cipla Limited | ₹1,08,090 Cr | 27.9 | 11.74% | ₹7,119 Cr | -14.7% |
| Laurus Labs Ltd | ₹1,06,442 Cr | 119.8 | 17.74% | ₹2,026 Cr | +125.7% |
| Dr.Reddys Lab | ₹1,02,010 Cr | 23.8 | 11.52% | ₹8,698 Cr | -0.9% |
| Mankind Pharma | ₹91,379 Cr | 47.8 | 12.45% | ₹4,031 Cr | -9.9% |
| Aurobindo Pharma Ltd. | ₹90,432 Cr | 26 | 9.93% | ₹9,150 Cr | +41.7% |
| Lupin Ltd | ₹88,018 Cr | 16.5 | 26.91% | ₹8,277 Cr | -1.1% |
| Smruthi Organics Ltd | ₹153 Cr | 44.6 | 4.72% | ₹29 Cr | +2.7% |
Listed by market capitalisation. Ratios are shown for context only.
Smruthi Organics Ltd is trading at ₹133.50, with a market capitalisation of ₹153 Cr.
Smruthi Organics Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Smruthi Organics Ltd has a P/E of 44.6 and a return on equity of 4.72%.
Smruthi Organics Ltd is listed on the BSE under the scrip code 540686.
Smruthi Organics Ltd's share price is up 2.7% over one year and up 17.1% over three months. Its 52-week range is ₹95.00 to ₹175.30.
In Q1 FY27, Smruthi Organics Ltd reported revenue of ₹29 Cr and net profit of ₹3 Cr, with basic EPS of ₹2.57 (standalone, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.